Advertisement
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
No AccessJournal of UrologyAdult Urology1 Apr 2015

The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer

    View All Author Information

    Purpose:

    The Prostate Health Index (phi) is a new test combining total, free and [-2]proPSA into a single score. It was recently approved by the FDA and is now commercially available in the U.S., Europe and Australia. We investigate whether phi improves specificity for detecting clinically significant prostate cancer and can help reduce prostate cancer over diagnosis.

    Materials and Methods:

    From a multicenter prospective trial we identified 658 men age 50 years or older with prostate specific antigen 4 to 10 ng/ml and normal digital rectal examination who underwent prostate biopsy. In this population we compared the performance of prostate specific antigen, % free prostate specific antigen, [-2]proPSA and phi to predict biopsy results and, specifically, the presence of clinically significant prostate cancer using multiple criteria.

    Results:

    The Prostate Health Index was significantly higher in men with Gleason 7 or greater and “Epstein significant” cancer. On receiver operating characteristic analysis phi had the highest AUC for overall prostate cancer (AUCs phi 0.708, percent free prostate specific antigen 0.648, [-2]proPSA 0.550 and prostate specific antigen 0.516), Gleason 7 or greater (AUCs phi 0.707, percent free prostate specific antigen 0.661, [-2]proPSA 0.558, prostate specific antigen 0.551) and significant prostate cancer (AUCs phi 0.698, percent free prostate specific antigen 0.654, [-2]proPSA 0.550, prostate specific antigen 0.549). At the 90% sensitivity cut point for phi (a score less than 28.6) 30.1% of patients could have been spared an unnecessary biopsy for benign disease or insignificant prostate cancer compared to 21.7% using percent free prostate specific antigen.

    Conclusions:

    The new phi test outperforms its individual components of total, free and [-2]proPSA for the identification of clinically significant prostate cancer. Phi may be useful as part of a multivariable approach to reduce prostate biopsies and over diagnosis.

    References

    • 1 : Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med2012; 157: 120. Google Scholar
    • 2 : Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet2014; 384: 2027. Google Scholar
    • 3 : Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst2012; 104: 125. Google Scholar
    • 4 : Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol1993; 150: 100. LinkGoogle Scholar
    • 5 : Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol2013; 63: 986. Google Scholar
    • 6 : Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol2003; 170: 723. LinkGoogle Scholar
    • 7 : A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol2011; 185: 1650. LinkGoogle Scholar
    • 8 : ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology2011; 77: 763.e1. Google Scholar
    • 9 : Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol2012; 188: 1131. LinkGoogle Scholar
    • 10 : The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol2014; 140: 257. Google Scholar
    • 11 : Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol2010; 50: 921. Google Scholar
    • 12 : Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol2007; 178: 2359. LinkGoogle Scholar
    • 13 : New confidence intervals for the difference between two sensitivities at a fixed level of specificity. Stat Med2006; 25: 3487. Google Scholar
    • 14 : Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics1988; 44: 837. Google Scholar
    • 15 : The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. Int Urol Nephrol2014; 46: 711. Google Scholar
    • 16 : Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range. World J Urol2013; 31: 305. Google Scholar
    • 17 : Multicenter evaluation of [-2]proprostate-specific antigen and the Prostate Health Index for detecting prostate cancer. Clin Chem2013; 59: 306. Google Scholar
    • 18 : Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med2013; 51: 729. Google Scholar
    • 19 National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection Version 2014. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Accessed May 26, 2014. Google Scholar
    • 20 : Reducing unnecessary biopsies for suspicion of prostate cancer: extension and validation of an ERSPC based risk calculator with phi and comparison with the PCPT risk calculator including %free and -2proPSA. J Urol2013; 189: e843. abstract 2054. LinkGoogle Scholar
    • 21 Roobol M, Salman J and Azevedo N: The Rotterdam prostate cancer risk calculator: improved prediction with more relevant pre-biopsy information, now in the palm of your hand. Presented at EAU Stockholm, April 11-15, 2014, abstract 857. Google Scholar
    • 22 : Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol2010; 183: 534. LinkGoogle Scholar
    • 23 : Prostate Health Index (Phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One2013; 8: e67687. Google Scholar
    • 24 : Overdiagnosis and overtreatment of prostate cancer. Eur Urol2014; 65: 1046. Google Scholar
    Advertisement